Tagged: sanofi
4 results
Dynavax Technologies
Dynavax Technologies is an Emeryville, California biopharmaceutical company built around CpG 1018, a proprietary vaccine adjuvant that sharpens the immune system's response. Its flagship product, HEPLISAV-B, is the first and only two-dose adult hepatitis B vaccine approved in the U.S. and Europe, and had grown to roughly 44% U.S. market share by the end of 2024. Beyond hepatitis B, Dynavax licenses CpG 1018 to other vaccine developers - most visibly as an ingredient in several COVID-19 vaccines - and has advanced its own pipeline in shingles, plague, pandemic influenza, and Lyme disease. In December 2025 Sanofi agreed to acquire Dynavax for about $2.2 billion; the deal closed in February 2026.
Bozidar Jovicevic
Bozidar Jovicevic is the CEO and co-founder of Evermed, a New York startup that lets medical societies and healthcare organizations launch a Netflix-style, on-demand video library in about 90 days. A medical doctor and FIDE chess master who spent 17 years running global digital initiatives at Novartis and Sanofi, he now builds technology that turns conference recordings and expert lectures into searchable, monetizable continuing-education libraries for physicians. He also hosts the Pharma Launch Secrets and Digital Innovators Circle podcasts.
Michael Shih
Michael Shih is the Chief Executive Officer of NeoPhore Ltd, a London-based small molecule neoantigen immuno-oncology company developing first-in-class drugs that target the DNA mismatch repair (MMR) pathway to make cancers more visible to the immune system. An attorney by training with degrees in biology, he spent nearly two decades structuring biotech deals before sitting in the chief executive's chair, with senior business development and corporate development roles at Kite Pharma, Biogen, Sanofi, Epizyme, Forest Laboratories, Kastle Therapeutics and Eisai. He took the helm at NeoPhore in December 2024, right after the company closed an oversubscribed Series B round backed by Bristol Myers Squibb.
Formation Bio
Formation Bio is a New York-based, AI-native pharmaceutical company that acquires and in-licenses clinical-stage drug candidates and runs them through a proprietary, technology-driven development platform to bring treatments to patients faster and at lower cost. Formerly known as TrialSpark, the company rebranded in December 2023 and raised a $372M Series D in June 2024 led by Andreessen Horowitz and Sanofi. It pairs in-house drug selection expertise with AI tools for trial design, recruitment, regulatory writing, and safety monitoring, and partnered with OpenAI and Sanofi to build purpose-built AI agents for drug development.